CN101961311B - 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法 - Google Patents

一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法 Download PDF

Info

Publication number
CN101961311B
CN101961311B CN201010292234XA CN201010292234A CN101961311B CN 101961311 B CN101961311 B CN 101961311B CN 201010292234X A CN201010292234X A CN 201010292234XA CN 201010292234 A CN201010292234 A CN 201010292234A CN 101961311 B CN101961311 B CN 101961311B
Authority
CN
China
Prior art keywords
injection
beta
androstane
alkane
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201010292234XA
Other languages
English (en)
Other versions
CN101961311A (zh
Inventor
颜光美
胡海燕
张静夏
邱鹏新
李玲
田宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Cellprotek Pharmaceutical Co Ltd
Original Assignee
National Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Sun Yat Sen University filed Critical National Sun Yat Sen University
Priority to CN201010292234XA priority Critical patent/CN101961311B/zh
Publication of CN101961311A publication Critical patent/CN101961311A/zh
Priority to LTEP11826361.5T priority patent/LT2620153T/lt
Priority to AU2011304917A priority patent/AU2011304917B2/en
Priority to PT118263615T priority patent/PT2620153T/pt
Priority to PCT/CN2011/076968 priority patent/WO2012037834A1/zh
Priority to RU2013105216/15A priority patent/RU2532354C1/ru
Priority to KR1020137006176A priority patent/KR101468153B1/ko
Priority to HUE11826361A priority patent/HUE038230T2/hu
Priority to PL11826361T priority patent/PL2620153T3/pl
Priority to DK11826361.5T priority patent/DK2620153T3/en
Priority to US13/821,849 priority patent/US9161985B2/en
Priority to CA2809646A priority patent/CA2809646C/en
Priority to TR2018/09354T priority patent/TR201809354T4/tr
Priority to BR112013005763-7A priority patent/BR112013005763B1/pt
Priority to SG10201400723UA priority patent/SG10201400723UA/en
Priority to EP11826361.5A priority patent/EP2620153B1/en
Priority to RS20180765A priority patent/RS57409B1/sr
Priority to ES11826361.5T priority patent/ES2677069T3/es
Priority to SG2013016126A priority patent/SG188393A1/en
Priority to SI201131508T priority patent/SI2620153T1/en
Priority to JP2013527453A priority patent/JP5750680B2/ja
Application granted granted Critical
Publication of CN101961311B publication Critical patent/CN101961311B/zh
Priority to US14/839,869 priority patent/US9265837B1/en
Priority to HRP20181002TT priority patent/HRP20181002T1/hr
Priority to CY181100681T priority patent/CY1120724T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

本发明公开了一种5α-雄甾(烷)-3β，5，6β-三醇注射剂(简称YC-6)及其制备方法。方案为：使用羟丙基-β-环糊精作为增溶剂，优选比例为：YC-6占1-20份，羟丙基-β-环糊精占40-500份。其他组份的比例可以优选：等渗调节剂1-100份，冻干填充剂0-200份，溶剂0-2000份。制备方法是，将羟丙基-β-环糊精溶液、YC-6和其他可溶性辅料按顺序分别溶于注射用水中，经脱色去热原、过滤；滤液灭菌后制得液态注射剂；滤液干燥后制得固态注射剂。本发明的优点在于：使YC-6作为急救用药，注射给药成为可能。并具有溶解度稳定，无刺激性、疗效稳定和制备工艺简单易得等优点。

Description

一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
技术领域
本发明涉及制药领域，具体涉及一种5α-雄甾(烷)-3β，5，6β-三醇注射剂及其制备方法。
背景技术
5α-雄甾(烷)-3β，5，6β-三醇(下面简称为YC-6)是我们新发现的神经保护剂。目前，急性缺血性脑卒中的治疗主要通过两个途径：一为溶解血栓，二为神经保护。由于神经保护剂可减少脑梗死面积，不引发出血，无溶栓、抗凝治疗出血的并发症，用前无需进行详细的病因鉴别诊断，使得早期治疗成为可能，已成为脑卒中治疗的研究热点。
然而，迄今为止还没有发现已证明为安全有效的神经保护剂，目前正在进行临床试验的、具有潜在临床应用前景的药物有钙通道阻滞剂(CCB)、钙通道调节剂、谷氨酸释放抑制剂、GABA受体激动剂、自由基清除剂、抗细胞间黏附分子抗体等。在众多化合物中，神经活性甾体对神经保护具有广泛效应而日益受到关注。特别是YC-6，作为新发现的神经保护剂，其作用不限于神经保护。在体内外对脑缺血及脊髓缺血均有效，日剂量为50-100mg。但由于YC-6在水中溶解度小，常用的非水溶剂及其混合溶剂虽然可提高其溶解度，但均存在较大的刺激性，并且有经水稀释后析出的现象，从而影响了该制剂的疗效和安全性，限制了注射剂的YC-6的广泛应用。
发明内容
为了克服以上缺陷，本发明提供了一种YC-6注射剂及其制备方法。该发明使用羟丙基-β-环糊精作为增溶剂，成功地解决了目前YC-6注射剂使用过程中澄明度不稳定和刺激性的问题。
为实现上述目的，本发明的YC-6注射剂，包括液态注射液或固态注射液。注射液配方的可溶性辅料中含有羟丙基-β-环糊精。当然，该注射液的可溶性辅料还可以包括等渗调节剂或冻干填充剂。
YC-6与羟丙基-β-环糊精重量的优选重量份数比为：1-20∶40-500。
注射剂中各组分占的重量百分比也可按：YC-61-20份，羟丙基-β-环糊精40-500份，等渗调节剂1-100份，冻干填充剂0-200份，溶剂0-2000份，进行配制。
所述的等渗调节剂可以包括氯化钠、葡萄糖、甘露醇、乳糖、木糖醇、山梨醇或麦芽糖醇中的一种或几种。
所述的冻干填充剂包括氯化钠、葡萄糖、甘露醇、乳糖、木糖醇、山梨醇或麦芽糖醇中的一种或几种。
如果配制液态注射剂，溶剂可以选用丙二醇、乙醇、聚乙二醇400、聚乙二醇200、甘油或水中的一种或几种。
本发明的注射液可以通过以下制备方法得到：首先，将羟丙基-β-环糊精溶液、YC-6和其他可溶性辅料按顺序分别溶于注射用水中，经脱色、过滤、灭菌得“注射液”。
制备“冻干粉针”的方法是：将上述过滤后的滤液灌装于安瓿中，冷冻干燥，得“冻干粉针”。
制备“无菌粉针”的方法是：将上述滤液喷雾干燥，分装得到“无菌粉针”。
上述方法中，可以使用0.1-0.3％的活性炭进行脱色，灭菌的温度和时间为115℃灭菌30分钟或121℃灭菌15分钟。
当然，也可以利用同原理将YC-6制成葡萄糖注射液、氯化钠注射液或葡萄糖氯化钠注射液。
本发明与现有技术相比具有以下优越的技术效果：
本发明通过采用了羟丙基-β-环糊精或非水溶剂/混合溶剂，提高了YC-6的溶解度，使YC-6可以制成以水、非水溶剂或混合溶剂为溶剂的注射液、注射用无菌粉末、冻干粉针、葡萄糖注射液、氯化钠注射液或葡萄糖氯化钠注射液。使YC-6作为急救用药，注射给药成为可能。并具有溶解度稳定，无刺激性、疗效稳定和制备工艺简单易得等优点。
具体实施方式
实施例1：本实施例制备200支YC-6注射液(规格5ml:50mg)。
配方为：
YC-6                      10g
2-羟丙基-β-环糊精        200g
氯化钠                    1.25g
注射用水加至              1000ml
制备工艺：取羟丙基-β-环糊精，溶于处方量80％的新鲜注射用水中，加入YC-6室温搅拌10-20分钟，使全溶。加入氯化钠，搅拌使溶解，添加注射用水至足量，遂加入0.1％的活性碳60℃保温15分钟，放冷，经0.22μm微孔滤膜过滤。滤液灌封为5ml注射液，121℃灭菌15分钟，即得。
实施例2：本实施例制备200支YC-6注射剂(规格10ml:80mg)
YC-6                 16g
3-羟丙基-β-环糊精   400g
葡萄糖               13.9g
注射用水加至         2000ml
制备工艺：取羟丙基-β-环糊精，溶于处方量80％的新鲜注射用水中，加入YC-6室温搅拌10-20分钟，使全溶。加入葡萄糖，搅拌使溶解，添加注射用水至足量，遂加入0.1％的活性碳60℃保温15分钟，放冷，经0.22μm微孔滤膜过滤。滤液灌封得10ml注射液。121℃灭菌15分钟，即得。
实施例3：本实施例制备200支YC-6注射剂(规格5ml:100mg)
YC-6                 20g
2-羟丙基-β-环糊精   400g
注射用水加至         1000ml
制备工艺：取羟丙基-β-环糊精，溶于处方量80％的新鲜注射用水中，加入YC-6，室温搅拌10-20分钟使全溶，添加注射用水至足量，遂加入0.1％的活性碳60℃保温15分钟，放冷，经0.22μm微孔滤膜过滤。滤液灌封得5ml注射液。115℃灭菌30分钟，即得。
实施例4：本实施例制备200支YC-6无菌粉末(规格80mg/支)
YC-6                   16g
2-羟丙基-β-环糊精     400g
氯化钠                 2.5g
分装成                 200支
制备工艺：取羟丙基-β-环糊精溶于处方量80％的新鲜注射用水中，溶解后，加入YC-6，室温搅拌10-20分钟，使全溶。加入氯化钠，搅拌使溶解，添加注射用水至2000ml。遂加入0.1％的活性碳60℃保温15分钟，放冷，经0.22μm微孔滤膜过滤。滤液喷雾干燥，分装成200支，即得。
实施例5：本实施例制备200支YC-6冻干粉针(规格5ml:60mg)
YC-6                   12g
3-羟丙基-β-环糊精     200g
葡萄糖                 7g
注射用水加至           1000ml
制备工艺：取羟丙基-β-环糊精溶于处方量80％的新鲜注射用水中，溶解后，加入YC-6，室温搅拌10-20分钟，使全溶。加入氯化钠，搅拌使溶解，添加注射用水至2000ml。遂加入0.1％的活性碳60℃保温15分钟，放冷，经0.22μm微孔滤膜过滤，滤液分装为5ml/西林瓶，冷冻干燥，即得。
实施例6 YC-6注射剂与常用输液配伍的稳定性研究取实施例1中所述的YC-6注射液2支(5ml×2)加入常用输液中，考察YC-6注射剂与常用输液8h内的配伍稳定性。考察项目包括色泽、澄明度、pH及YC-6含量，结果如下表所示。
表1YC-6注射剂与常用输液配伍方案
  样品号   配伍(25-30℃)
  A   YC-6注射液5ml*2支+5％葡萄糖注射液250ml
  B   YC-6注射液5ml*2支+0.9％氯化钠注射液250ml
  C   YC-6注射液5ml*2支+葡萄糖氯化钠注射液250ml
  D   YC-6注射液5ml*2支+复方氯化钠注射液500ml
  E   YC-6注射液5ml*2支+5％碳酸氢钠注射液250ml
表2常用输液与YC-6注射液配伍后色泽与澄明度的变化
表3常用输液与YC-6注射液配伍后pH的变化
Figure BSA00000283721600062
Figure BSA00000283721600071
表4常用输液与YC-6注射液配伍后输液中YC-6的含量变化(μg/ml)
  样品号   0h   2h   8h   24h
  A   375.4   364.7   367.7   363.4
  B   379.2   373.5   380.4   386.1
  C   385.6   387.6   383.4   384.5
  D   382.0   383.7   387.2   380.8
  E   386.7   375.1   381.3   376.5
实施例7 YC-6的初步安全性评价
将昆明小鼠按体重分笼后，随机分为五组，每组10只，雌雄各半。尾静脉注射不同剂量的实施例3项下的YC-6注射液(20mg/ml)，并立即记录现象，存活小鼠观察一周后处死，逐天记录动物毒性反应情况及死亡数，计算LD50及95％可信限。YC-6的LD50＞400±121mg/kg。
取新鲜新西兰兔血，按常规方法制备血球，并用生理盐水稀释成2％的混悬液，加入注射剂，37℃温孵3小时，比色法测定溶血率。结果表明，注射剂溶血率小于1％。
取白色豚鼠，按常规方法进行过敏试验，结果表明YC-6注射液不引起豚鼠过敏反应。
用新西兰兔进行静脉注射血管刺激性试验。结果表明用药组耳缘静脉的组织变化与对照组相似，各兔耳缘静脉血管壁完整，未见内皮损伤、周围组织水肿等病理变化，静脉血管结构正常。

Claims (9)

1.5α-雄甾(烷)-3β，5，6β-三醇注射剂，包括液态注射剂或固态注射剂，所述注射剂的配方由5α-雄甾(烷)-3β，5，6β-三醇、注射用溶剂及可溶性辅料组成，其特征在于：所述的可溶性辅料包括增溶剂，所述的增溶剂为羟丙基-β-环糊精；其中5α-雄甾(烷)-3β，5，6β-三醇与羟丙基-β-环糊精的重量份数比为：1-20∶40-500。
2.如权利要求1所述的注射剂，其特征在于：所述的可溶性辅料还包括等渗调节剂或冻干填充剂中的一种或两种。
3.如权利要求2所述的注射剂，其特征在于，该注射剂中各组分占的重量份数比是：5α-雄甾(烷)-3β，5，6β-三醇1-20份，羟丙基-β-环糊精40-500份，等渗调节剂1-100份，冻干填充剂0-200份，注射用溶剂0-2000份。
4.如权利要求2所述的注射剂，其特征在于，所述的等渗调节剂选自氯化钠、葡萄糖、甘露醇、乳糖、木糖醇、山梨醇或麦芽糖醇中的一种或几种。
5.如权利要求2所述的注射剂，其特征在于，所述的冻干填充剂选自氯化钠、葡萄糖、甘露醇、乳糖、木糖醇、山梨醇或麦芽糖醇中的一种或几种。
6.如权利要求2所述的注射剂，其特征在于，所述的注射用溶剂选自丙二醇、乙醇、聚乙二醇400、聚乙二醇200、甘油或水中的一种或几种。
7.如权利要求1所述的注射剂的制备方法，其特征在于，将羟丙基-β-环糊精、5α-雄甾(烷)-3β，5，6β-三醇和其他可溶性辅料按顺序分别溶于注射用溶剂中，经脱色去热原、过滤得滤液，上述滤液灭菌得“注射液”；或将上述滤液灌装于安瓿中，冷冻干燥，得“冻干粉针”；或将上述滤液喷雾干燥，分装得“无菌粉针”。
8.如权利要求7所述的注射剂的制备方法，其特征在于，所述的脱色步骤中所用的吸附剂是活性炭，用量为注射剂的质量百分比的0.05-0.3％。
9.如权利要求8所述的注射剂的制备方法，其特征在于，所述的灭菌步骤的温度和时间分别是：115℃灭菌30分钟或121℃灭菌15分钟。
CN201010292234XA 2010-09-21 2010-09-21 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法 Active CN101961311B (zh)

Priority Applications (24)

Application Number Priority Date Filing Date Title
CN201010292234XA CN101961311B (zh) 2010-09-21 2010-09-21 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
TR2018/09354T TR201809354T4 (tr) 2010-09-21 2011-07-08 5 alfa androstan (alkil) 3 beta,5,6 beta triol enjeksiyonu ve Bunun hazırlanmasına yönelik yöntem.
SG10201400723UA SG10201400723UA (en) 2010-09-21 2011-07-08 5 a-Androstane (Alkyl)-3ß, 5, 6ß – Triol Injection And Preparation Method Therefor
PT118263615T PT2620153T (pt) 2010-09-21 2011-07-08 Injecção de 5α-androstano-3β,5,6β-triol e método de preparação desta
PCT/CN2011/076968 WO2012037834A1 (zh) 2010-09-21 2011-07-08 一种5α-雄甾（烷）-3β，5，6β-三醇注射剂及其制备方法
RU2013105216/15A RU2532354C1 (ru) 2010-09-21 2011-07-08 ИНЪЕКЦИОННАЯ ФОРМА 5α АНДРОСТАН-3β,5,6β-ТРИОЛА И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
KR1020137006176A KR101468153B1 (ko) 2010-09-21 2011-07-08 5α-안드로스테인-3β,5,6β-트리올 주사제 및 제조방법
HUE11826361A HUE038230T2 (hu) 2010-09-21 2011-07-08 5 alfa-androsztán (alkil)-3ß,5,6ß-triol injekció és eljárás annak elõállítására
PL11826361T PL2620153T3 (pl) 2010-09-21 2011-07-08 Zastrzyk 5alfa-androstano(alkilo)-3beta,5,6beta-triolu i sposób jego wytwarzania
DK11826361.5T DK2620153T3 (en) 2010-09-21 2011-07-08 5 ALPHA-ANDROSTAN (ALKYL) -3 BETA, 5,6 BETA-TRIOL INJECTION AND PROCEDURE FOR PREPARING THEREOF
US13/821,849 US9161985B2 (en) 2010-09-21 2011-07-08 5α-androstane (alkyl)-3β, 5, 6β-triol injection and preparation method therefor
CA2809646A CA2809646C (en) 2010-09-21 2011-07-08 5.alpha.-androstane-3.beta.,5,6.beta.-triol injection and preparation method therefor
LTEP11826361.5T LT2620153T (lt) 2010-09-21 2011-07-08 5 alfa-androstano (alkil)-3 beta,5,6 beta-triolio injekcija ir jos gavimo būdas
BR112013005763-7A BR112013005763B1 (pt) 2010-09-21 2011-07-08 Injeção de 5a-androstano-3ss, 5, 6ss-triol e método para prrparação da injeção
AU2011304917A AU2011304917B2 (en) 2010-09-21 2011-07-08 5alpha-androstane (alkyl)-3beta,5,6beta-triol injection and preparation method therefor
EP11826361.5A EP2620153B1 (en) 2010-09-21 2011-07-08 5 alpha-androstane (alkyl)-3 beta,5,6 beta-triol injection and preparation method therefor
RS20180765A RS57409B1 (sr) 2010-09-21 2011-07-08 Injekcija 5 alfa-androstan (alkil)-3 beta,5,6 beta-triola i postupak njene pripreme
ES11826361.5T ES2677069T3 (es) 2010-09-21 2011-07-08 Inyección de 5 alfa-androstano (alquil)-3 beta,5,6 beta-triol y su método de preparación
SG2013016126A SG188393A1 (en) 2010-09-21 2011-07-08 5ALPHA-ANDROSTANE (ALKYL)-3ß,5,6ß-TRIOL INJECTION AND PREPARATION METHOD THEREFOR
SI201131508T SI2620153T1 (en) 2010-09-21 2011-07-08 5 Alpha-androstane (alkyl) -3beta, 5.6 beta-triol injection and the preparative method of this
JP2013527453A JP5750680B2 (ja) 2010-09-21 2011-07-08 ５α−アンドロスタン−３β，５，６β−トリオール注射剤及びその調製方法
US14/839,869 US9265837B1 (en) 2010-09-21 2015-08-28 5α-androstane-3β,5,6β-triol injection and preparation method therefor
HRP20181002TT HRP20181002T1 (hr) 2010-09-21 2018-06-28 Injekcija 5 alfa-androstan (alkil)-3 beta, 5, 6 beta-triola i postupak pripreme
CY181100681T CY1120724T1 (el) 2010-09-21 2018-06-29 Ενεση 5 αλφα-ανδροστανο (αλκυλο)-3-βητα,5,6 βητα-τριολης και μεθοδος παρασκευης για αυτη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201010292234XA CN101961311B (zh) 2010-09-21 2010-09-21 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法

Publications (2)

Publication Number Publication Date
CN101961311A CN101961311A (zh) 2011-02-02
CN101961311B true CN101961311B (zh) 2012-11-21

Family

ID=43514490

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201010292234XA Active CN101961311B (zh) 2010-09-21 2010-09-21 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法

Country Status (22)

Country Link
US (2) US9161985B2 (zh)
EP (1) EP2620153B1 (zh)
JP (1) JP5750680B2 (zh)
KR (1) KR101468153B1 (zh)
CN (1) CN101961311B (zh)
AU (1) AU2011304917B2 (zh)
BR (1) BR112013005763B1 (zh)
CA (1) CA2809646C (zh)
CY (1) CY1120724T1 (zh)
DK (1) DK2620153T3 (zh)
ES (1) ES2677069T3 (zh)
HR (1) HRP20181002T1 (zh)
HU (1) HUE038230T2 (zh)
LT (1) LT2620153T (zh)
PL (1) PL2620153T3 (zh)
PT (1) PT2620153T (zh)
RS (1) RS57409B1 (zh)
RU (1) RU2532354C1 (zh)
SG (2) SG10201400723UA (zh)
SI (1) SI2620153T1 (zh)
TR (1) TR201809354T4 (zh)
WO (1) WO2012037834A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809309B2 (en) * 2010-07-09 2014-08-19 Guangzhou Cellprotek Pharmaceutical Ltd. Use of 5α-androstane (alkyl)-3β,5,6β-triol in preparation of neuroprotective drugs

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102617685B (zh) 2012-03-08 2014-01-22 广州市赛普特医药科技有限公司 雄甾-3β,5α,6β-三醇的晶型化合物及其制备方法
CN103330946B (zh) * 2013-05-29 2015-03-25 广州市赛普特医药科技有限公司 5α-雄甾-3β,5,6β-三醇注射剂其制备方法
CN104288110B (zh) * 2013-06-26 2017-05-10 广州市赛普特医药科技股份有限公司 5α‑雄甾‑3β,5,6β‑三醇注射剂及其制备方法
WO2015047999A1 (en) * 2013-09-26 2015-04-02 Polyone Corporation Sustainable poly(vinyl halide) mixtures for thin-film applications
CN109985047B (zh) * 2017-12-29 2021-07-27 广州市赛普特医药科技股份有限公司 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2191576A (en) * 1936-11-21 1940-02-27 Soc Of Chemical Ind 3,5,6-trihydroxy androstane and pregnane compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
US5563131A (en) * 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
AU718232B2 (en) * 1995-11-13 2000-04-13 Supergen, Inc. Improved formulation for administration of steroid compounds
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CN1232539C (zh) * 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
WO2004070048A1 (en) * 2003-02-07 2004-08-19 Pharmacia & Upjohn Company Llc A microbial process to prepare 5-androsten-3beta, 7alpha, 15alpha-triol-17-one and related analogues
CN1706501A (zh) * 2005-05-27 2005-12-14 沈阳药科大学 亲脂性药物环糊精包合物的制备方法
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2191576A (en) * 1936-11-21 1940-02-27 Soc Of Chemical Ind 3,5,6-trihydroxy androstane and pregnane compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
李群等.孕甾烷-3β,5α,6β-三醇抑制低钾诱导的小脑颗粒神经元凋亡.《中国药理学与毒理学杂志》.2001,第15卷(第5期),第337-341页. *
蔡翔等.海洋甾体YC-1抑制低钾诱导大鼠小脑颗粒神经元的凋亡.《中山医科大学学报》.2000,第21卷(第3期),第161-164页. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809309B2 (en) * 2010-07-09 2014-08-19 Guangzhou Cellprotek Pharmaceutical Ltd. Use of 5α-androstane (alkyl)-3β,5,6β-triol in preparation of neuroprotective drugs
US9320743B2 (en) 2010-07-09 2016-04-26 Guangzhou Cellprotek Pharmaceutical Ltd. Use of 5α-androstane-3β,5,6β-triol in preparation of neuroprotective drugs

Also Published As

Publication number Publication date
EP2620153A4 (en) 2016-07-13
CN101961311A (zh) 2011-02-02
CA2809646C (en) 2016-03-08
US20130172307A1 (en) 2013-07-04
RU2532354C1 (ru) 2014-11-10
DK2620153T3 (en) 2018-07-23
US9265837B1 (en) 2016-02-23
EP2620153B1 (en) 2018-04-18
RS57409B1 (sr) 2018-09-28
AU2011304917B2 (en) 2014-10-23
ES2677069T3 (es) 2018-07-27
HUE038230T2 (hu) 2018-10-29
KR20130073945A (ko) 2013-07-03
SI2620153T1 (en) 2018-08-31
TR201809354T4 (tr) 2018-07-23
WO2012037834A1 (zh) 2012-03-29
JP5750680B2 (ja) 2015-07-22
LT2620153T (lt) 2018-10-10
SG188393A1 (en) 2013-04-30
JP2013537170A (ja) 2013-09-30
US20160051685A1 (en) 2016-02-25
EP2620153A1 (en) 2013-07-31
AU2011304917A1 (en) 2013-03-14
RU2013105216A (ru) 2014-10-27
HRP20181002T1 (hr) 2018-08-24
CY1120724T1 (el) 2019-12-11
SG10201400723UA (en) 2014-10-30
BR112013005763A2 (pt) 2020-07-07
PT2620153T (pt) 2018-07-18
BR112013005763B1 (pt) 2021-06-15
CA2809646A1 (en) 2012-03-29
US9161985B2 (en) 2015-10-20
KR101468153B1 (ko) 2014-12-01
PL2620153T3 (pl) 2018-09-28

Similar Documents

Publication Publication Date Title
CN101961311B (zh) 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
EP2827862A1 (en) Formulations of bendamustine
CN102100666B (zh) 一种新的盐酸莫西沙星注射剂
CN102481287B (zh) 含维生素c或其衍生物的替莫唑胺药物组合物及其制备方法
CN103054883B (zh) 一种含有果糖二磷酸钠化合物的药物组合物
CN103393693A (zh) 一种盐酸昂丹司琼和地塞米松的药物组合物
CN103830223A (zh) 香叶木素在制备治疗心血管疾病的药物中的应用
CN104940135A (zh) 一种氟康唑注射液及其制备方法
CN102688183A (zh) 一种稳定的盐酸莫西沙星注射剂
CN102210686A (zh) 一种含更昔洛韦化合物的药物组合物及其制备方法
CN102008461B (zh) 一种注射用布洛芬药物组合物
CN103385877B (zh) 一种紫杉醇和西咪替丁的药物组合物
CN103520186B (zh) 一种注射用脂溶性维生素的药物组合物及其制备方法
CN105311040A (zh) 一种含有果糖二磷酸钠的用于治疗循环系统疾病的新药物组合物针剂
CN100377712C (zh) 葫芦素脂质体组方及其制剂
CN103585119A (zh) 一种包含依前列醇及其药用盐的稳定化制剂及其制备方法
CN103040737A (zh) 一种含有兰索拉唑化合物的药物组合物及其制备方法
CN103330946B (zh) 5α-雄甾-3β,5,6β-三醇注射剂其制备方法
CN103385883B (zh) 一种含盐酸托烷司琼和果糖的药物组合物
CN102895232B (zh) 一种含头孢尼西化合物药物组合物及其制备方法
CN102764437B (zh) 甲氧沙林注射液及其制备方法
WO2018120920A1 (zh) 一种苯磺顺阿曲库铵冻干粉针制剂
CN100563664C (zh) 一种液体药剂及其制备方法和用途
CN103393685A (zh) 一种含奥沙利铂和氟尿嘧啶的药物组合物
CN113559261A (zh) 一种硼携带剂注射剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
EE01 Entry into force of recordation of patent licensing contract

Assignee: Guangzhou Saipute Medical Technology Co., Ltd.

Assignor: Sun Yat-sen University

Contract record no.: 2011440000671

Denomination of invention: Preparation of N,N,N',N',-tetraacetyl-3,5,3',5'-tetrabromo(chloro)-4,4'-diaminodiphenyl methane

License type: Exclusive License

Open date: 20110202

Record date: 20110712

EC01 Cancellation of recordation of patent licensing contract

Assignee: Guangzhou Saipute Medical Technology Co., Ltd.

Assignor: Sun Yat-sen University

Contract record no.: 2011440000671

Date of cancellation: 20120911

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: GUANGZHOU SEPATEC PHARMACEUTICAL TECHNOLOGY CO., L

Free format text: FORMER OWNER: SUN YAT-SEN UNIVERSITY

Effective date: 20121205

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 510080 GUANGZHOU, GUANGDONG PROVINCE TO: 510663 GUANGZHOU, GUANGDONG PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20121205

Address after: 510663 Guangdong province Guangzhou Science City skim Springs Road No. 3, Guangzhou international business incubator C208

Patentee after: Guangzhou Saipute Medical Technology Co., Ltd.

Address before: 510080 Guangzhou 74 north campus, two Zhongshan Road, Guangdong, China

Patentee before: Sun Yat-sen University

C56 Change in the name or address of the patentee
CP03 Change of name, title or address

Address after: The city on 510663 Guangzhou Road, Guangdong province science No. 3 Guangzhou International Business Incubator Building G 401-415

Patentee after: GUANGZHOU SAIPUTE PHARMACEUTICAL TECHNOLOGY CO., LTD.

Address before: 510663 Guangdong province Guangzhou Science City skim Springs Road No. 3, Guangzhou international business incubator C208

Patentee before: Guangzhou Saipute Medical Technology Co., Ltd.